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Abstract 
Background: Operational tolerance is an alternative to lifelong immunosuppression after transplantation. One 
strategy to achieve tolerance is by T regulatory cells. Safety and feasibility of a T regulatory type 1 (Tr1)-cell—based 
therapy to prevent graft versus host disease in patients with hematological malignancies has been already proven. We 
are now planning to perform a Tr1-cell—based therapy after kidney transplantation.
Methods: Upon tailoring the lab-grade protocol to patients on dialysis, aims of the current work were to develop 
a clinical-grade compatible protocol to generate a donor-specific Tr1-cell—enriched medicinal product (named 
T10 cells) and to test the Tr1-cell sensitivity to standard immunosuppression in vivo to define the best timing of cell 
infusion.
Results: We developed a medicinal product that was enriched in Tr1 cells, anergic to donor-cell stimulation, able 
to suppress proliferation upon donor- but not third-party stimulation in vitro, and stable upon cryopreservation. The 
protocol was reproducible upon up scaling to leukapheresis from patients on dialysis and was effective in yielding the 
expected number of T10 cells necessary for the planned infusions. The tolerogenic gene signature of circulating Tr1 
cells was minimally compromised in kidney transplant recipients under standard immunosuppression and it eventu-
ally started to recover 36 weeks post-transplantation, providing rationale for selecting the timings of the cell infusions.
Conclusions: These data provide solid ground for proceeding with the trial and establish robust rationale for defin-
ing the correct timing of cell infusion during concomitant immunosuppressive treatment.
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Background
Circulating T regulatory type 1 (Tr1) cells with an 
alloantigen-specific regulatory function have been con-
sistently associated with operational tolerance after 
transplantation [1]. Alloantigen-specific Tr1 cells can be 
induced in  vitro in the presence of exogenous IL-10 or 
by tolerogenic IL-10-producing dendritic cells (DC-10) 
and they are hyporesponsive (anergic) to the alloantigen 
used for their generation [2, 3]. These IL-10-anergized T 
cells have been tested as medicinal product in a proof-
of-concept trial in patients undergoing haploidentical 
hematopoietic stem cell transplantation (HSCT) to pro-
vide immune reconstitution in the absence of severe graft 
versus host disease (GvHD) (the ALT-TEN trial) [4].
The ONE Study—a European Commission FP7-funded 
consortium-aims to test several distinct haematopoi-
etic immunoregulatory cells as therapies after kidney 
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of independent clinical trials based on the same gen-
eral design [5]. Our group participates in this consor-
tium to test donor-specific Tr1 cells. The ALT-TEN trial 
already performed was certainly instrumental although 
the know-how that was developed in this first clini-
cal experience did not necessarily allow performing The 
ONE Study faster and more efficiently. We overcame the 
first hurdle of tailoring the Tr1-cell generation proto-
col to patients on dialysis, yet only at a lab-scale [6]. In 
this study, we aimed at: (1) defining a reproducible and 
clinical-grade compatible protocol for the generation of 
a Tr1-cell—enriched medicinal product for kidney trans-
plant recipients, (2) characterizing the final cell product, 
and (3) testing the sensitivity of circulating Tr1 cells to 
immunosuppressive therapy to determine the ideal tim-
ing of the medicinal product infusion.
Methods
Healthy donors and patients
Peripheral blood, buffy coat or leukapheresis were 
obtained from healthy donors or renal transplant recipi-
ents enrolled in The ONE Study Reference Group Trial 
(i.e., control group in which patients were treated with 
standard immunosuppressive therapy) (NCT01656135) 
after written informed consent in accordance with the 
Declaration of Helsinki under the protocol approved 
by the San Raffaele Hospital’s Ethics Committee (IRB 
#OSR-TheOne).
Generation and characterization of dendritic cells
Peripheral blood mononuclear cells (PBMC) were iso-
lated by density-gradient centrifugation on Lymphoprep 
(Axis-Shield, Oslo, Norway). IL-10-producing dendritic 
cells (DC-10) and mature DC (mDC) were generated 
from healthy donors [7]. Monocytes were isolated by 
harvesting the adherent fraction of PBMC or by selec-
tion with CD14+ microbeads using the AutoMACS sys-
tem (Miltenyi Biotec, Bergisch Gladbach, Germany) and 
following manufacturer’s instructions. Monocytes were 
cultured with 10  ng/ml rhIL-4 (GMP-grade, Miltenyi 
Biotec) and 100  ng/ml rhGM-CSF (GMP-grade, Milte-
nyi Biotec) for 7 days in the presence (DC-10) or absence 
(mDC) of 10  ng/ml rhIL-10 (GMP-grade, CellGenix 
GmbH, Freiburg, Germany). The culture medium was 
supplemented with GMP-grade fetal bovine serum (FBS) 
(Lonza, Basel, Switzerland) or GMP-grade human AB 
sera (Lonza). mDC were matured during the last 2 days 
of culture with 5 µg/ml of rMPL-A (GMP-grade, Invivo-
gen, Toulouse, France). At the end of the 7-day cultures, 
DC-10 and mDC were harvested and irradiated at 60 Gy 
with a Cs137 source Biobeam 2000 irradiator (Gamma-
Service Medical GmbH, Leipzig, Germany). DC-10 yield 
was measured as: 100× [no. of generated DC-10 cells/no. 
of plated cells].
Supernatants were collected 48 h after culturing DC-10 
in the presence or absence of stimulation by lipopoly-
saccharide (LPS) from Escherichia coli (5μg/ml, Sigma 
Chemicals, St. Louis, MO). IL-10 released into the super-
natant was quantified by ELISA (BD Pharmingen, San 
Diego, CA). The detection limit of IL-10 was 15 pg/ml.
Generation and characterization of Tr1‑ cell enriched 
product: T10 cells
CD4+ T cells were isolated from donors different from 
those used to generate DC by CD4+ microbeads using 
the AutoMACS system (Miltenyi Biotec) following man-
ufacturer’s instructions. Purified CD4+ T cells were cul-
tured with irradiated allogeneic DC-10 or mDC (10:1 
ratio) in the presence or absence of exogenous rhIL-10 
(10 ng/ml) for 10 days to generate T10 or control Tm cells, 
respectively (Fig.  1) [8]. T10-cell yield was measured as: 
100× [no. of T10 cells generated/no. CD4+ T cells plated]. 
To test the generation of donor-specific anergic T cells, 
T10 and Tm cells were cultured with the original-donor 
mDC (previously frozen) and cell proliferation was moni-
tored via 3H-thymidine (PerkinElmer, Waltham, MA, 
USA) incorporation (counts per min, cpm) in the last 
16–18  h of a 3-day culture. Anergy was calculated as: 
cpm [(T10 +  mDC)/(Tm +  mDC)] ×100. Supernatants 
were collected before 3H-thymidine addition and quanti-
fication of IFNγ or IL-10 by ELISA (BD Pharmingen) was 
performed. The detection limit of IFN-γ was 15 pg/ml.
Ability of T10 cells to suppress the proliferation of 
autologous CD4+ T cells upon donor or third party mDC 
stimulation was assessed by 3H-thymidine incorporation 
in the last 16–18 h of a 5-day culture.
Flow cytometry
The immune phenotype of in  vitro generated DC, T10 
and Tm cells was tested by flow cytometry as previously 
described [8]. The TCR Vβ repertoire was determined 
with the IOTest® Beta Mark TCR V beta Repertoire Kit 
(Beckman Coulter, Inc, Brea, CA, USA) following manu-
facturer’s instructions.
Cells were analyzed with the BD FACS Canto II (Beck-
ton Dickinson, San Jose, CA, USA) within few hours 
after staining. Data was analyzed using FCS 3.0 (DeNovo 
Instruments, Los Angeles, CA, USA).
Dual IFNγ/IL‑10 ELISPOT
Dual IFNγ/IL-10 ELISPOT (Diaclone, Besancon, France) 
was performed according to manufacturer’s instruc-
tions with a slight modification: visualization of IL-10 
was performed using Vector Blue Alkaline Phosphatase 
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substrate kit (Vector Labs, Burlingame, CA, USA) and 
the A.EL.VIS 4-Plate ELISPOT Reader (A.EL.VIS GmbH, 
Hannover, Germany) was used. Analysis was performed 
using ImageJ (version 1.48, NIH, USA) to quantify IFNγ-
producing cells (red spots), IL-10-producing cells (blue 
spots) or dual IFNγ/IL-10-producing cells (purple spots).
Transcript analysis of purified Tr1 cells
Peripheral blood was collected and PBMC were fro-
zen from patients enrolled in The ONE Study Reference 
Group Trial at our center at the following time points: 
4-weeks pre-transplant, 8- 36- and 60-weeks post-
transplant. PBMC were thawed and Tr1-cell sorting was 
performed using MoFlo Legacy Cell Sorter (Beckman 
Coulter, Indianapolis, IN, USA). To verify the expression 
of anti-inflammatory genes characteristic of Tr1 cells (as 
previously described [1]) and pro-inflammatory genes 
characteristic of T effector cells (i.e., il-17a, il-1b, tnf, il-6 
and ifnγ), QuantiGene 15-plex assay (Affymetrix, Santa 
Clara, CA, USA) was performed following manufactur-
er’s instructions. Mean fluorescence intensity from the 
measured beads per gene was reported using Bio-Plex 
200 system (BioRad Laboratories, Hercules, CA, USA). 
Probe set information is provided in Additional file 1.
Statistical analysis
Comparisons between groups were performed using Stu-
dent’s t test, Mann–Whitney test or Wilcoxon matched 
pairs test depending on the experiments. For all analyses, 
a two-tailed p value  ≤0.05 was considered significant. 
Comparison of variances was performed using the F-test. 
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Fig. 1 Graphical representation of the protocol for generating T10 cells to be used in kidney transplanted patients. CD14
+ cells are selected from 
the kidney donor leukapheresis and cultured with GM-CSF and IL-4 in the presence (DC-10) or absence (mDC) of IL-10. At day 5, mDC are activated 
with monophosphoril MPL. Upon harvest at day 7 of culture, DC-10 and mDC are irradiated and co-cultured for 10 days with CD4+ T cells selected 
from the recipient leukapheresis and exogenous IL-10 to generate T10 cells. mDC cultured with CD4
+ T cells without IL-10 generate the control Tm 
cell population. T10 cells are donor-specific anergic CD4
+ T cells, yet they respond to third party mDC stimulation (IIIp mDC) similar to the control 
population as shown by the representative cell-proliferation bars (simulating what one should expect when measuring T10 cell proliferation toward 
donor mDC or toward third party unrelated mDC)
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Prism version 6.0 (GraphPad Software, San Diego, CA, 
USA).
Results
DC‑10 generation in compliance with clinical‑grade 
manufacturing
The generation of donor-specific Tr1 cells is contingent 
to the production of donor-derived DC-10 [7]. The first 
step in defining a clinical-grade compatible protocol 
was therefore establishing an efficient and reproducible 
method for DC-10 generation. Based on the MLR/DC-10 
protocol used in the ALT-TEN trial [7], DC-10 were gen-
erated from the PBMC adherent fraction in medium sup-
plemented with fetal bovine serum (FBS) in wells. Due to 
the availability of GMP-compatible human serum (HS) 
and guidelines from the regulatory authorities on the 
use of bovine-derived sera (EMEA/CHMP Guideline on 
the use of bovine serum in the manufacture of human 
biological medicinal products—original version EMA/
CPMP/BWP/1793/02, and revised version EMA/CHMP/
BWP/457920/2012 rev 1), we compared FBS- and HS-
supplemented medium during DC-10 generation. The 
same batch of FBS was used throughout the experiments 
described throughout the manuscript. Alongside a cer-
tificate of analysis, we confirm the availability of a TSA 
Certificate of Suitability, issued by EDQM via the process 
of Certification of Suitability of Monographs of the Euro-
pean Pharmacopoeia. DC-10 recovery was better when 
medium supplemented with FBS was used, yet the intra-
experiment variability—determined by the coefficients 
of variation (CV)—was high (Fig. 2). This high variability 
could be attributed to the non-specific monocyte selec-
tion method, which leads to unpredictable monocyte 
recovery [9]. Thus, provided methods for clinical-grade 
monocyte selection are available, monocytes were puri-
fied by CD14+ magnetic beads and selected on mag-
netic columns [10]. DC-10 recovery was less variable 
upon starting from bead-selected monocytes than from 
adherence and FBS was necessary to generate sufficient 
DC-10 numbers (as shown in Fig. 2 and also supported 
by our unpublished results generated from independent 
unrelated experiments). DC-10 generated from purified 
CD14+ monocytes in FBS-supplemented medium had 
the anticipated phenotype (i.e, CD14+CD86+CD16+) and 
they produced IL-10, either at steady state or upon LPS 
activation (Fig. 3) [7]. Based on these data, we concluded 
that peripheral blood monocyte selection by CD14+ 
magnetic beads and culture media supplemented with 
FBS is the optimal clinical-grade compatible approach for 
DC-10 generation. This conclusion was drawn based on 
the limited number of DC-10 generated with HS that was 
incompatible with the clinical need. In addition, DC-10 
will be irradiated and kept in culture with recipient 
CD4+ T cells for 10 additional days in the absence of any 
bovine-derived products.
T10 cell generation in compliance with clinical‑grade 
manufacturing
A protocol for the generation of cell products to be 
infused into patients has to be solid and highly reproduc-
ible to have the highest chance to be used in clinical tri-
als. Accordingly, buffy coats from eight healthy donors 
were used for DC-10 generation and buffy coats from 
eight more donors were used for the isolation of CD4+ T 
cells. Flasks were used as clinical-grade compatible cul-
ture containers to generate T10 cells.
Monocytes isolated from buffy coats with lab-grade 
magnetic columns (AutoMACS-Miltenyi) had a mean 
purity of 95 ±  3% (mean ±  SD). DC-10 yield in flasks 
(13 ± 6, mean ± SD) was, as expected, lower than that 
in wells (23 ±  7, mean ±  SD) (Table  1) but all DC-10 
preparations in flasks had a tolerogenic phenotype 
(Fig. 3).
CD4+ T cells isolated from buffy coats with lab-
grade magnetic columns had a mean purity of 98 ±  1% 
(mean  ±  SD). Average T10-cell yield after 10  days 
of co-culture with allogeneic DC-10 was 53  ±  31% 
(mean  ±  SD) and T10-cell donor-specific anergy was 
80 ±  10% (mean ±  SD) (Table  1). The T10-cell product 
was constituted of 96 ± 4% (mean ± SD) CD4+ T cells; 
Fig. 2 CD14+ bead-selected monocytes cultured in FBS-supple-
mented medium represent an optimal clinical-grade compatible 
approach for DC-10 generation. Adherent fraction of PBMC (empty 
square) or CD14+ selected monocytes (filled square) were cultured in 
FBS- or HS-supplemented medium for 7 days to generate tolero-
genic Tr1-cell-inducing DC-10. DC-10 yield is shown, measured as: 
100× [no. of generated DC-10 cells/no. of plated cells]. One square 
represents one experiment, lines represent mean value of each data 
set ± SD. Coefficient of variation (CV) is shown for each data set
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the remaining non-CD4+ T cells were donor-derived 
DC-10 cells that were irradiated and therefore dead or 
prone to die (Additional file 2). Coefficients of variation 
were high for both DC-10 and T10-cell yield, probably 
due to intrinsic differences among donors. The cut off 
anergy value for classifying T10 cells as anergic towards 
donor antigens was determined utilizing the “mean 
minus 2×  SD” as statistical method [11]. This method 
was chosen based on our previous experience in the ALT-
TEN trial [4]. Based on the eight T10-cell preparations 
generated from eight different donor pairs, the anergy 
cut off of T10 cells was 60%. Thus, T10-cell products for 
clinical-grade-compatible use will be considered anergic 
when the value is ≥60%.
Fig. 3 DC-10 have a tolerogenic phenotype and produce IL-10. One representative (out of eight) flow cytometry staining of DC-10 cells and control 
mDC gated on live cells. Percentages of CD14+ cells (upper left panel a), CD86+ cells (middle left panel a) and CD16+ cells (lower left panel a) are 
shown. Bars represent mean value of each data set ± SD for DC-10 and mDC (upper right panel a). Bars represent mean value of IL-10 (quantified by 
ELISA) ±SD secreted by DC-10 or mDC upon 48-h of culture in the presence or absence of LPS stimulation (b)
Table 1 Protocol reproducibility with  the optimized clinical-grade compatible conditions using buffy coats from  eight 
donor pairs
DC-10 tolerogenic dendritic cells, SD standard deviation, CV coefficient of variation
CD14+ purity (%) DC‑10 yield (%) CD4+ purity (%) T10‑cell yield (%) Donor‑specific anergy (%)
Mean 95 13 98 53 80
SD 3 6 1 31 10
Range 90–99 4–21 97–99 17–123 63–94
CV 3.3 47.3 0.9 59.0 14.6
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Based on our previous murine studies we plan to infuse a 
total of 2 × 106 T10 cells/kg [12]. Given the DC-10 and T10-
cell yield observed, buffy coats would fail to provide suffi-
cient numbers of monocytes and CD4+ T cells to reach the 
required number of T10 cells. Up scaling from buffy coats 
to leukapheresis was therefore a necessary step [13]. As a 
proof-of-concept, leukapheresis from two healthy donors 
were used as sources of CD14+ cells for the generation 
of DC-10 cells. To generate T10 cells, leukapheresis from 
two patients with kidney failure on dialysis were used as 
sources of CD4+ T cells. This setting mimics exactly the 
clinical situation that we will face during the future clinical 
trial. The yield of T10 cells from both donor pairs surpassed 
the minimum number required for the planned infusions 
(2 × 106/kg): 11 × 106 cells/kg (#001) and 19 × 106 cells/
kg (#002). T10 cells displayed donor-specific anergy higher 
than 60% (Fig. 4). In addition to this, 3 more donor pairs 
were recruited in the study and T10 cells were successfully 
generated from leukapheresis in a GMP-compatible facility 
(Battaglia et al. manuscript in preparation), further proving 
protocol up scaling. These data demonstrate that the proto-
col for the generation of clinical-grade-compatible T10 cells 
defined by using buffy coats is also applicable to leukapher-
esis. Additionally, these data confirm our previous work tai-
loring the protocol to patients on dialysis [8]. A statistically 
significant positive correlation existed between the expres-
sion of the activation marker CD86 on DC-10 and T10-cell 
yield (Additional file 3). These data suggest that for DC-10 
to generate antigen-specific T10 cells in vitro, they need to 
have an appropriate level of activation.
In vitro characterization of the medicinal product
Additional important functional features of T10 cells, that 
go beyond the development of the clinical-grade-compat-
ible protocol, were also tested to better characterize the 
cells that will be infused into patients. As we had previ-
ously reported, the medicinal products generated in vitro 
with DC-10 are enriched in Tr1 cells and are comprised 
not only of Tr1 cells, but also CD4+ memory T cells that 
respond to nominal antigens [7]. To test the Tr1-cell con-
tent in the T10 cells generated with the clinical-grade-
compatible protocol described above, the frequency of 
CD4+CD45RA−CD49b+LAG-3+ cells (i.e., Tr1 cells [14]) 
was tested by flow cytometry. T10 cells contained an aver-
age of 6 ± 3% (mean ± SD) Tr1 cells, while control Tm 
cells lacked Tr1 cells (Fig.  5a). Tr1-cell content in T10 
cells generated from patients on dialysis using leukapher-
esis products was comparable to that in T10 cells gener-
ated from healthy donors using buffy coats (open versus 
closed squares, respectively Fig. 5a). The Tr1-cell content 
in T10 cells was irrespective of the frequency of Tr1 cells 
originally present in the starting CD4+ T-cell population, 
supporting the notion of de novo generation of donor-
specific Tr1 cells rather than the expansion of circulating 
Tr1 cells (Fig. 5b).
Treg-cell function is commonly tested in  vitro by 
means of suppression assays [14, 15]. These assays are 
cumbersome and difficult to be used as standard tests in 
clinical-grade labs. However, the demonstration that T10 
cells have in  vitro suppressive activity further supports 
their potential efficacy in  vivo in patients. The in  vitro 
ability of T10 cells to suppress proliferation of autologous 
CD4+ T cells in response to donor-mDC was therefore 
tested. To prove donor-specific regulation, suppression 
of autologous CD4+ T cell responses towards third party 
allogeneic mDC was also tested when numbers of T10 
cells permitted. Priority was given to anergy tests, being 
most relevant in the upcoming Phase 1 trial testing the 
safety of T10 cells. All, except one T10-cell preparation, 
suppressed in  vitro proliferation of autologous CD4+ 
T cells in response to donor-mDC but not to third 
party-mDC stimulation proving their antigen-specific 
regulatory properties (Fig.  6a). Importantly, a positive 
correlation between Tr1-cell content and the suppressive 
capacity of T10 cells was observed thus further suggest-
ing that the in vitro regulation of T10 cells is mediated by 
Tr1 cells (Fig. 6b). Interestingly, a strong correlation was 
observed when Tr1-cell content exceeded 5% indicating 
that T10 cell preparations—to have a good suppressive 
capacity—need to contain at least 5% of Tr1 cells: CD4
+CD45RA−CD49b+LAG-3+. To note, one preparation 
resulted in T10 cells with no suppressive capacity and low 
Tr1-cell content. However, the anergy level of these T10 
cells was 84%, suggesting that even with a low Tr1-cell 
Fig. 4 Protocol for T10-cell generation is reproducible upon up 
scaling from buffy coats to leukapheresis. CD4+ T cells purified from 
leukapheresis from two patients with kidney failure on dialysis were 
co-cultured with allogeneic DC-10 cells (generated from leukapher-
esis from two healthy donors) to generate T10 cells. Counts per min 
(cpm) of incorporated 3H-thymidine in the last 16–18 h of a 3-day co-
culture of T10 or Tm cells with donor-mDC are shown. Bars represent 
mean value of cpm of T10 or Tm cells (in triplicates) generated from 
patient #001 and #002. Percentage of anergy of T10 cells is indicated 
over the bars
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Fig. 5 T10 cells are enriched in Tr1 cells. One representative flow cytometry staining (out of eight) of CD49b
+LAG-3+ cells gated on CD4+CD45RA− 
of CD4+ T cells, control Tm cells and T10 cells is shown (upper panel a). Percentages of CD49b
+LAG-3+ (within CD4+CD45RA−) Tr1 cells are shown. 
Each closed square represents one experiment with buffy coats from healthy donors; each open square represents one experiment with leukaphere-
sis from patients on dialysis. Lines represent mean value of each data set ± SD (lower panel a). Percentages of Tr1 cells in the starting CD4+ T cells are 
plotted against percentages of Tr1 cells within the corresponding T10 cells. One dot represents one experiment. Line represents linear regression (b)
Fig. 6 Donor-specific suppression of CD4+ T cell proliferation by T10 cells correlates with Tr1-cell content. CD4
+ T cells were stimulated with donor 
mDC (or third party mDC—when numbers of T10 cells permitted) in the presence or absence of autologous T10 cells. Percentages of suppression by 
T10 cells are shown. One dot represents one experiment with buffy coats from healthy donors (each symbol depicts one donor and different shapes 
represent different donor pairs). Lines represent mean value of each data set ±SD (*p ≤ 0.05 Wilcoxon matched pairs test) (a). Percentages of Tr1-
cell content within T10 cells is plotted against percentage of suppression by T10 cells. One dot represents one experiment. Numbers represent anergy 
levels measured on each T10-cell preparation. Line represents linear regression (b)
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content these cells remain anergic towards donor stimu-
lation, hence complying with the safety requirement of 
this medicinal product.
A high number of IL-10-producing cells and a low 
number of IFNγ-producing cells in response to donor-
mDC stimulation was detected by dual ELISPOT in T10 
cells, as compared to those detected in control Tm cells 
(Fig.  7a). This was confirmed by the levels of IL-10 and 
IFNγ by ELISA in the supernatant of co-culture of T10 
cells with donor-mDC (Fig. 7b).
T10 cells maintained a polyclonal TCR-Vβ repertoire 
proving lack of a skewed immune response in  vitro 
(Additional file 4) supporting previous findings [4].
We anticipate the infusion of T10 cells in patients only 
upon obtaining all safety data (i.e., quality controls and 
anergy values) on the medicinal product. Thus, cryo-
preservation of T10 cells is inevitable. However, not 
all cell products are suitable for freezing and thaw-
ing, requiring additional manipulation to restore their 
functionality upon thawing [16, 17]. We thus aimed at 
testing cell product viability and safety upon various 
cryopreservation time-points. All T10 cells had a viabil-
ity ≥70% upon thawing (after 1, 6 or 12 months of cryo-
preservation) and preserved their Tr1-cell content (data 
not shown). All T10-cell preparations tested, remained 
anergic upon donor-mDC stimulation and preserved 
Tr1 content when thawed (Fig.  8). For limited cell 
number availability, the suppressive ability and/or the 
cytokine production profile of thawed products could 
not be tested. We gave priority to the anergy test, given 
that it provides a clear answer on the safety of thawed 
medicinal products. These data provide evidence that 
T10 cells can be cryopreserved up to 12 months without 
losing their viability, stability and donor-specific anergy 
upon thawing and do not require further manipulation 
prior to in vivo infusion. Similar data were obtained with 
the 3 GMP-grade generated medicinal products (Battag-
lia et al. manuscript in preparation).
Fig. 7 T10 cells produce more IL-10 and less IFNγ than control Tm cells in response to donor- but not third party-mDC stimulation. T10 or control Tm 
cells were stimulated with donor-mDC or third party-mDC. Cytokine-forming units (CFU) were detected by dual ELISPOT for IFNγ and/or IL-10. Num-
ber of CFU/100,000 cells is shown. Bars represent mean value of each dataset ±SD (n = 3 experiments) (a). T10 or control Tm cells were stimulated 
with donor-mDC. IL-10 and IFNγ measured in the supernatant 48 h after culture by ELISA is shown. One dot represents one experiment with buffy 
coats from healthy donors (each symbol depicts one donor and different shapes represent different donor pairs). Lines represent mean value of each 
data set ± SD (ns, **p < 0.005 Mann–Whitney test) (b)
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Gene signature of circulating Tr1 cells is transiently 
affected by immunosuppressive drugs
The ONE Study trial with donor-specific Tr1 cells infused 
into patients undergoing kidney transplantation envisages 
the concomitant administration of immunosuppressive 
drugs [5]. Thus, the obvious question on administer-
ing cell therapy under active immunosuppression is the 
effect of the selected drugs on Tr1-cell viability and sta-
bility/function in vivo [18]. The ONE Study also included 
a parallel clinical trial with no cell therapy but standard 
immunosuppressive treatment, to be used as a reference 
group for the analysis of cell therapy trials (Additional 
file 5, detailing immunosuppressive regimen). We aimed 
at monitoring whether circulating endogenous Tr1 cells 
preserve their gene signature under standard immuno-
suppressive therapy: il10hi, il4lo, il17lo, tgfβhi/int, pd1hi, 
granzyme bhi, (reviewed in [1]). To this aim, circulating 
Tr1 cells of two patients enrolled in the Reference Group 
Trial at our clinical site were studied (Additional file  6 
detailing immunosuppression dosages and trough levels). 
The frequency and gene expression profile of circulat-
ing Tr1 cells purified from patients after kidney trans-
plant and under active immunosuppression (8, 36 and 
60 weeks post-transplant) was compared to those of cir-
culating Tr1 cells purified from the same patients before 
transplant (4 weeks pre-transplant) and in the absence of 
any drug treatment. Tr1 cells were detectable in the cir-
culation and were increased in frequency and absolute 
numbers (Fig. 9a). Tr1-cell frequency peaked at 8 weeks 
post-transplant then returned to pre-transplant levels in 
both patients (Additional file 7). This increase was likely 
due to homeostatic proliferation after induction therapy, 
as observed in memory CD4+ T cells (Fig. 9b) [19]. Tr1 
cells were isolated by flow cytometry-based cell sorting 
(Additional file 8 for gating strategy). The gene signature 
typical of Tr1 cells [14] was slightly diminished (patient 
#003) or remained unchanged (patient #004) at 8 weeks 
post-transplant and then returned to pre-transplant lev-
els or heightened at 60 weeks post-transplant (in the two 
patients, respectively) (Fig. 9c).
These data suggest that Tr1 cells expand along with 
the CD4+ T-cell memory population and that the Tr1-
cell tolerogenic gene expression profile remains stable 
even under active immunosuppressive treatment. Data 
are limited to two patients (being the only patients we 
enrolled in the reference group trial) but they attempted 
to dissect the Tr1-cell sensitivity to immunosuppres-
sion in vivo, a relevant concern that was—to our knowl-
edge—never addressed before. Importantly, these data 
suggest that the best timing of ex  vivo-generated Tr1-
cell infusion could be right at the moment of transplant 
(to reduce inflammation and control alloreactivity) and 
around 36 weeks post-transplant, when the Tr1-cell sig-
nature starts to recover.
Discussion
Optimization of a clinical-grade compatible protocol 
for generating donor-specific Tr1-enriched cell medici-
nal products is a pre-requisite for the planned clinical 
trial in kidney transplant recipients [5]. In this study we 
described a clinical-grade compatible protocol that ena-
bled the production of donor-specific Tr1-cell enriched 
medicinal product (named T10 cells) by coculturing 
recipient CD4+ T cells with tolerogenic donor DC-10 
in the presence of exogenous IL-10 for 10  days. The 
generated T10 cells are anergic and suppressive towards 
donor stimulation in  vitro, maintain a stable function 
upon cryopreservation and are successfully produced 
in clinically sufficient amounts starting from leukapher-
esis from patients on dialysis. We also demonstrated that 
Fig. 8 Freezing has little effect on donor-specific anergy and Tr1-cell content of T10 cells. T10 cells were thawed after 1, 6 or 12 months of freezing 
and immediately stimulated with donor-mDC. In parallel, flow cytometry staining for Tr1 cells was performed. Percentages of donor-specific anergy 
(a) and Tr1 cell content (b) are shown. One symbol represents one T10 cell preparation starting from buffy coats from healthy donors. Lines represent 
the time course of the percentage of anergy or Tr1-cell content of individual T10 cells thawed at different timepoints. Dotted line represents the set 
cutoff anergy level of 60%. Tr1-cell content 12 months after freezing was not available
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Fig. 9 Gene signature of circulating Tr1 cells of two kidney transplant recipients is transiently affected by immmunosuppression. Percentages of Tr1 
cells before (4 weeks pre-transplant) and after kidney transplantation (8, 36, 60 weeks) are shown. One line represents one patient (a). Percentages 
of circulating CD4+CD45RA− T memory cells (within CD3+ T cells) in the two patients are shown (b). Transcript analysis of the indicated genes was 
performed on purified circulating Tr1 cells from patient #003 and #004. Bubble chart represents the gene expression signals for each patient over 
time: 4 weeks pre-transplant, 8-, 36- and 60-weeks post-transplant (normalized to housekeeping gene hprt1). Bubble size represents gene expres-
sion signal. Gene symbols are represented on the right (c)
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circulating Tr1 cells have a limited sensitivity (in terms of 
viability and gene expression profile) to standard immu-
nosuppressive treatment in vivo.
Several hurdles are encountered when attempting to 
perform cell therapy clinical trials [18]. First, the pro-
tocol for generating the medicinal product needs to be 
clinical-grade. To that end, we surpassed all the obsta-
cles. Second, a sufficient number of cells to be infused is 
a prerequisite. Up scaling to leukapheresis could, in some 
instances, represent a hurdle in terms of sample collec-
tion and protocol adaptability [20]. Here we proved that 
leukapheresis can be collected with no medical con-
tra-indications from patients on dialysis and that both 
tolerogenic DC-10 and T10 cells can be generated from 
leukapheresis products.
Another key aspect is the definition of lab tests that 
ensure safety of the cell product. Within The ONE Study 
consortium, some groups are using polyclonal Tregs. We 
decided to invest in the donor-specific Tr1-cell-based 
therapy in an attempt to promote antigen-specific toler-
ance. However, the generation of T10 cells with donor-
derived DC, although they are tolerogenic and well 
characterized [3, 7], contains an intrinsic risk of generat-
ing alloreactive T cells that, once infused, could be poten-
tially risky for the patient leading to graft rejection. The 
ONE Study Cell Therapy Trials are feasibility and safety 
trials [5]. Thus, in vitro assays that prove medicinal-prod-
uct safety are mandatory. Donor-specific anergy is an 
optimal assay to test T10-cell safety, while the suppression 
assay provides indications on the possible efficacy of Tr1 
cells in vivo. Accordingly, T10 cells that show no suppres-
sive capacity in vitro but retain donor-specific anergy are 
considered safe and therefore will be infused in patients 
participating in The ONE Study cell therapy trial at our 
institute.
Some groups working with FOXP3+ Tregs as cell ther-
apy products, reported problems with cryopreservation, 
thus requiring—for instance—further cell manipulation 
upon thawing [16, 17]. The demonstration that T10 cells 
are stable and conserve their Tr1-cell content and donor-
specific anergy properties upon cryopreservation, allows 
for flexibility in their preparation and feasibility for more 
than one infusion.
Whether infused T10 cells retain their viability and 
function in vivo under treatment with immunosuppres-
sive drugs remains an important open question. One 
approach to address this issue was by testing the effect 
of immunosuppressive drugs in  vitro on the ex  vivo-
expanded human FOXP3+ Tregs or by using human-
ized mouse models [21]. This showed detrimental 
dose-dependent effects of immunosuppressive treat-
ments on viability and proliferative capacity while sparing 
the immunosuppressive function of FOXP3+ Tregs. We 
approached this issue by analyzing the frequency and 
the gene signature of circulating Tr1 cells collected from 
renal transplant recipients under active immunosuppres-
sive treatment. Our data suggest that immunosuppres-
sive drugs do not affect Tr1 cells since the cells remain in 
circulation and a transient change in the intensity of the 
gene signature is observed. Based on these data, we chose 
two different timings of T10-cell infusion to increase the 
chance of obtaining in vivo immune regulation. The first 
dose will be infused at the time of transplant (for Tr1-
cell enrichment just around the transplant period). The 
second dose will be infused at 36 weeks post-transplant, 
timepoint in which the Tr1-cell signature is recovering.
Taken together, our results demonstrate the reproduc-
ibility of an optimized clinical-grade-compatible proto-
col for generating Tr1-enriched T10 cells. The necessary 
following steps for performing the trial in patients are 
underway.
Conclusion
We describe the steps undertaken to achieve and vali-
date a reproducible optimized clinical-grade compatible 
protocol capable of generating donor-specific Tr1 cells 
in sufficient numbers. Additionally, selecting the tim-
ing of infusion of Tr1 cells to patients under immuno-
suppression remains an open question. We provide data 
assessing the viability and gene signature of circulating 
Tr1 cells in the presence of active immunosuppression 
thus supporting our rationale for selecting the timing of 
the planned infusions. We believe that this study high-
lights the importance of optimizing and validating Tr1 
cell manufacturing protocols to bring them closer to the 
bedside.
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dritic cells; FBS: fetal bovine serum; GMP: good manufacturing practice; GvHD: 
graft versus host disease; HS: human serum; HSCT: hematopoietic stem cell 
transplantation; LPS: lipopolysaccharide; mDC: mature dendritic cells; MLR/
DC-10: medicinal product constituted of donor PBMC anergized with irradi-
ated host DC-10; PBMC: peripheral blood mononuclear cells; Tm: effector T 
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